MA43460A1 - Nouveaux peptides, combinaisons de peptides et supports pour utilisation dans le traitementimmunothérapeutique de divers cancers - Google Patents

Nouveaux peptides, combinaisons de peptides et supports pour utilisation dans le traitementimmunothérapeutique de divers cancers

Info

Publication number
MA43460A1
MA43460A1 MA43460A MA43460A MA43460A1 MA 43460 A1 MA43460 A1 MA 43460A1 MA 43460 A MA43460 A MA 43460A MA 43460 A MA43460 A MA 43460A MA 43460 A1 MA43460 A1 MA 43460A1
Authority
MA
Morocco
Prior art keywords
peptides
cells
carriers
present
various cancers
Prior art date
Application number
MA43460A
Other languages
English (en)
Inventor
Toni Weinschenk
Jens Fritsche
Harpreet Singh
Andrea Mahr
Oliver Schoor
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of MA43460A1 publication Critical patent/MA43460A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4634—Antigenic peptides; polypeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)

Abstract

La présente invention concerne des peptides, des protéines, des acides nucléiques et des cellules pour utilisation dans des procédés immunothérapeutiques. La présente invention concerne, en particulier, l'immunothérapie du cancer. La présente invention concerne, en outre, des épitopes peptidiques des lymphocytes t associés à une tumeur, seuls ou en combinaison avec d'autres peptides associés à une tumeur, qui peuvent, par exemple, servir de principes pharmaceutiques actifs pour des compositions vaccinales qui stimulent les réponses immunitaires antitumorales, ou pour stimuler des lymphocytes t ex vivo et les transférer aux patients. Des peptides liés aux molécules du complexe majeur d'histocompatibilité (cmh), ou des peptides en tant que tels, peuvent également être des cibles d'anticorps, de récepteurs des lymphocytes t solubles et d'autres molécules de liaison.
MA43460A 2015-08-28 2016-08-26 Nouveaux peptides, combinaisons de peptides et supports pour utilisation dans le traitementimmunothérapeutique de divers cancers MA43460A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1515321.6A GB201515321D0 (en) 2015-08-28 2015-08-28 Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
PCT/EP2016/070146 WO2017036936A1 (fr) 2015-08-28 2016-08-26 Nouveaux peptides, combinaisons de peptides et supports pour utilisation dans le traitement immunothérapeutique de divers cancers

Publications (1)

Publication Number Publication Date
MA43460A1 true MA43460A1 (fr) 2019-08-30

Family

ID=54326487

Family Applications (7)

Application Number Title Priority Date Filing Date
MA042694A MA42694A (fr) 2015-08-28 2016-08-26 Nouveaux peptides, combinaisons de peptides et supports pour utilisation dans le traitement immunothérapeutique de divers cancers
MA43458A MA43458A1 (fr) 2015-08-28 2016-08-26 Nouveaux peptides, combinaisons de peptides et supports pour utilisation dans le traitementimmunothérapeutique de divers cancers
MA43460A MA43460A1 (fr) 2015-08-28 2016-08-26 Nouveaux peptides, combinaisons de peptides et supports pour utilisation dans le traitementimmunothérapeutique de divers cancers
MA43457A MA43457A1 (fr) 2015-08-28 2016-08-26 Nouveaux peptides, combinaisons de peptides et supports pour utilisation dans le traitementimmunothérapeutique de divers cancers
MA43459A MA43459A1 (fr) 2015-08-28 2016-08-26 Nouveaux peptides, combinaisons de peptides et supports pour utilisation dans le traitementimmunothérapeutique de divers cancers
MA045073A MA45073A (fr) 2015-08-28 2016-08-26 Nouveaux peptides, combinaison de peptides et d'échafaudages destinés à être utilisés dans le traitement immunothérapeutique de divers cancers
MA43461A MA43461B1 (fr) 2015-08-28 2016-08-26 Nouveaux peptides, combinaisons de peptides et supports pour utilisation dans le traitementimmunothérapeutique de divers cancers

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MA042694A MA42694A (fr) 2015-08-28 2016-08-26 Nouveaux peptides, combinaisons de peptides et supports pour utilisation dans le traitement immunothérapeutique de divers cancers
MA43458A MA43458A1 (fr) 2015-08-28 2016-08-26 Nouveaux peptides, combinaisons de peptides et supports pour utilisation dans le traitementimmunothérapeutique de divers cancers

Family Applications After (4)

Application Number Title Priority Date Filing Date
MA43457A MA43457A1 (fr) 2015-08-28 2016-08-26 Nouveaux peptides, combinaisons de peptides et supports pour utilisation dans le traitementimmunothérapeutique de divers cancers
MA43459A MA43459A1 (fr) 2015-08-28 2016-08-26 Nouveaux peptides, combinaisons de peptides et supports pour utilisation dans le traitementimmunothérapeutique de divers cancers
MA045073A MA45073A (fr) 2015-08-28 2016-08-26 Nouveaux peptides, combinaison de peptides et d'échafaudages destinés à être utilisés dans le traitement immunothérapeutique de divers cancers
MA43461A MA43461B1 (fr) 2015-08-28 2016-08-26 Nouveaux peptides, combinaisons de peptides et supports pour utilisation dans le traitementimmunothérapeutique de divers cancers

Country Status (18)

Country Link
US (7) US10525114B2 (fr)
EP (2) EP3461494A1 (fr)
JP (2) JP6970974B2 (fr)
KR (3) KR102308798B1 (fr)
CN (1) CN107921111B (fr)
AU (3) AU2016313684B2 (fr)
BR (1) BR112018003460A2 (fr)
CA (2) CA2996963A1 (fr)
CR (6) CR20200492A (fr)
EA (2) EA201891874A3 (fr)
GB (1) GB201515321D0 (fr)
MA (7) MA42694A (fr)
MX (1) MX2018002480A (fr)
PE (2) PE20181164A1 (fr)
SG (3) SG10202001830PA (fr)
TW (15) TWI722656B (fr)
UA (1) UA124577C2 (fr)
WO (1) WO2017036936A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201507030D0 (en) * 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
GB201515321D0 (en) * 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
SG11201804957VA (en) 2015-12-16 2018-07-30 Gritstone Oncology Inc Neoantigen identification, manufacture, and use
GB201609193D0 (en) 2016-05-25 2016-07-06 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
JP7075125B2 (ja) 2016-05-25 2022-05-25 イマティクス バイオテクノロジーズ ゲーエムベーハー 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ
KR102639592B1 (ko) 2016-12-08 2024-02-21 이매틱스 바이오테크놀로지스 게엠베하 짝짓기가 향상된 t 세포 수용체
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
CN108250286B (zh) * 2016-12-28 2021-06-08 香雪生命科学技术（广东）有限公司 源自于pasd1的肿瘤抗原短肽
BR112019021094A2 (pt) * 2017-04-10 2020-05-12 Immatics Biotechnologies Gmbh Peptídeos e combinações dos mesmos para uso na imunoterapia contra leucemias e outros cânceres
US10899819B2 (en) 2017-04-10 2021-01-26 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers
CR20200013A (es) 2017-07-14 2020-03-11 Immatics Biotechnologies Gmbh Molécula de polipéptido con especificidad dual mejorada
DE102017115966A1 (de) 2017-07-14 2019-01-17 Immatics Biotechnologies Gmbh Polypeptidmolekül mit verbesserter zweifacher Spezifität
MX2020003526A (es) * 2017-09-28 2020-09-14 Immpact Bio Ltd Una plataforma universal para la preparación de un receptor antigénico quimérico inhibidor (icar).
JP7227237B2 (ja) 2017-10-10 2023-02-21 グリットストーン バイオ インコーポレイテッド ホットスポットを利用した新生抗原の特定
CN111630602A (zh) 2017-11-22 2020-09-04 磨石肿瘤生物技术公司 减少新抗原的接合表位呈递
DE102018107224A1 (de) * 2018-02-21 2019-08-22 Immatics Biotechnologies Gmbh Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
TW202016131A (zh) * 2018-05-16 2020-05-01 德商英麥提克生物技術股份有限公司 用於抗癌免疫治療的肽
CN109467596B (zh) * 2018-11-12 2021-11-09 湖北省农业科学院畜牧兽医研究所 转录因子sp1在调控猪rtl1基因表达中的应用
CN109738929B (zh) * 2018-12-03 2022-10-21 中国辐射防护研究院 一种基于居民食物最大消费量的剂量估算方法及系统
JPWO2020171028A1 (fr) * 2019-02-18 2020-08-27
EP3970739A1 (fr) * 2019-05-13 2022-03-23 Itoh, Kyogo Procédé pour déterminer l'éligibilité de patients atteints d'un cancer pour une thérapie vaccinale peptidique
CN110123453B (zh) * 2019-05-31 2021-07-23 东北大学 一种基于无标记增强现实的手术导航系统
CA3173664A1 (fr) * 2020-04-14 2021-10-21 Claude Perreault Nouveaux antigenes specifiques a une tumeur pour la la leucemie lymphoblastique aigue (all)
CN111910000B (zh) * 2020-07-02 2022-07-01 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种预测鼻咽癌预后的肿瘤微环境成分标志物组合及系统
JP2024517630A (ja) * 2021-04-19 2024-04-23 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｍｈｃクラスｉペプチドを含む方法および組成物
CN115607573B (zh) * 2022-12-16 2023-05-23 北京大学第三医院（北京大学第三临床医学院） 一种用于调节杀伤性t细胞活性的方法、药物及其应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039434A1 (fr) * 1995-06-05 1996-12-12 Human Genome Sciences, Inc. Recepteur hgber32 de proteine g humaine
WO1999045954A1 (fr) * 1998-03-13 1999-09-16 Epimmune, Inc. Peptides de liaison de hla et leurs applications
US7342108B2 (en) * 1998-06-25 2008-03-11 The General Hospital Corporation De novo DNA cytosine methyltransferase genes, polypeptides and uses thereof
JP4315301B2 (ja) 1998-10-30 2009-08-19 独立行政法人科学技術振興機構 ヒトＨ３７タンパク質と、このタンパク質をコードする ｃＤＮＡ
US6680197B2 (en) * 1998-12-28 2004-01-20 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
CA2311201A1 (fr) * 1999-08-05 2001-02-05 Genset S.A. Sequences marqueurs exprimees et proteines humaines codees
US20040002068A1 (en) * 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
GB0119473D0 (en) 2001-08-09 2001-10-03 Astrazeneca Compounds
EP1425393A4 (fr) * 2001-08-21 2005-08-17 Millennium Pharm Inc Crible pour inhibiteurs de cdc7
US7193069B2 (en) * 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
DE10316701A1 (de) 2003-04-09 2004-11-04 Hinzmann, Bernd, Dr. Humane Nukleinsäuresequenzen aus Bronchialkarzinomen
EP1622934A2 (fr) * 2003-05-05 2006-02-08 Pharmacia Italia S.p.A. Formes tronquees de la dbf4 humaine, complexes avec leurs partenaires d'interaction et procedes destines a l'identification de leurs inhibiteurs
EP1522594A3 (fr) 2003-10-06 2005-06-22 Bayer HealthCare AG Methode et trousses pour evaluer un cancer
WO2005073374A1 (fr) * 2004-01-29 2005-08-11 Dainippon Sumitomo Pharma Co., Ltd. Nouvelle proteine d’antigène tumorale et son utilisation
WO2009008414A1 (fr) * 2007-07-10 2009-01-15 Shionogi & Co., Ltd. Anticorps monoclonal ayant une activité neutralisante contre le mmp13
ES2553270T3 (es) 2007-07-27 2015-12-07 Immatics Biotechnologies Gmbh Nuevo epítopo inmunogénico para inmunoterapia
CN103911358B (zh) * 2007-07-27 2017-03-01 伊玛提克斯生物技术有限公司 神经元和脑肿瘤的新型免疫疗法
WO2009051769A1 (fr) * 2007-10-17 2009-04-23 The Board Of Trustees Of The Leland Stanford Junior University Procédé et composition pour la cristallisation de récepteurs couplés aux glycoprotéines
CN102165688A (zh) 2008-03-31 2011-08-24 新加坡科技研究局 高效率线性发射器
TW201000115A (en) * 2008-06-11 2010-01-01 Oncotherapy Science Inc IQGAP3 epitope peptides and vaccines containing the same
DK2172211T3 (en) 2008-10-01 2015-02-16 Immatics Biotechnologies Gmbh Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
US20110318380A1 (en) * 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
ITBO20090075A1 (it) * 2009-02-13 2010-08-14 Magneti Marelli Spa Macchina elettrica con singolo statore e due rotori tra loro indipendenti e veicolo stradale provvisto di tale macchina elettrica
GB0911566D0 (en) * 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
US8710014B2 (en) * 2010-10-08 2014-04-29 Proteapex Therapeutics Llc Compositions and methods for inhibition of MMP13:MMP-substrate interactions
CN103458930B (zh) * 2011-02-01 2019-10-15 健玛保 针对cd74的人抗体和抗体-药物缀合物
CN104081202A (zh) 2011-09-12 2014-10-01 克里蒂科斯有限责任公司 检测靶分子的非侵入性方法
WO2013070603A1 (fr) 2011-11-11 2013-05-16 Cedars-Sinai Medical Center Compositions et méthodes de traitement de maladies rénales
US9878056B2 (en) * 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
EP2833923A4 (fr) 2012-04-02 2016-02-24 Moderna Therapeutics Inc Polynucléotides modifiés pour la production de protéines
US9500651B2 (en) * 2012-08-15 2016-11-22 Université de Montréal Method for identifying novel minor histocompatibility antigens
PT2895509T (pt) * 2012-09-14 2020-03-13 Us Health Recetores de células t que reconhecem mage-3 restrito a mhc de classe ii
US9134326B2 (en) 2013-03-14 2015-09-15 Battelle Memorial Institute Biomarkers for liver fibrosis
TWI777198B (zh) 2013-08-05 2022-09-11 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（七）
WO2015092710A1 (fr) * 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Administration simultanée controlatérale de vaccins
GB201515321D0 (en) 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
US20190346442A1 (en) * 2016-04-18 2019-11-14 The Broad Institute, Inc. Improved hla epitope prediction
TW202016131A (zh) 2018-05-16 2020-05-01 德商英麥提克生物技術股份有限公司 用於抗癌免疫治療的肽
US11945850B2 (en) 2018-09-17 2024-04-02 Immatics Biotechnologies Gmbh B*44 restricted peptides for use in immunotherapy against cancers and related methods

Also Published As

Publication number Publication date
CN107921111A (zh) 2018-04-17
UA124577C2 (uk) 2021-10-13
CR20200494A (es) 2020-11-24
TWI722656B (zh) 2021-03-21
TW202024127A (zh) 2020-07-01
TWI722653B (zh) 2021-03-21
BR112018003460A2 (pt) 2018-09-25
TW202024113A (zh) 2020-07-01
TW202024114A (zh) 2020-07-01
CR20180174A (es) 2018-06-06
TWI699377B (zh) 2020-07-21
TWI722658B (zh) 2021-03-21
MA42694A (fr) 2018-07-04
TWI722659B (zh) 2021-03-21
US10576132B2 (en) 2020-03-03
TW201920233A (zh) 2019-06-01
US10898557B2 (en) 2021-01-26
MA43458A1 (fr) 2019-08-30
TWI722661B (zh) 2021-03-21
US20200397879A1 (en) 2020-12-24
GB201515321D0 (en) 2015-10-14
TW202021613A (zh) 2020-06-16
TWI782290B (zh) 2022-11-01
JP2021118721A (ja) 2021-08-12
JP2018532382A (ja) 2018-11-08
US20200289631A1 (en) 2020-09-17
US20180250374A1 (en) 2018-09-06
US10898558B2 (en) 2021-01-26
EP3461494A1 (fr) 2019-04-03
US10695411B2 (en) 2020-06-30
EA201890560A1 (ru) 2018-08-31
US10568950B1 (en) 2020-02-25
US20180250373A1 (en) 2018-09-06
AU2018250464A1 (en) 2018-11-15
MA43461A1 (fr) 2019-08-30
TW202024111A (zh) 2020-07-01
TW202024126A (zh) 2020-07-01
CR20200495A (es) 2020-11-24
AU2020201896A1 (en) 2020-04-02
KR102515909B1 (ko) 2023-03-29
AU2020201896B2 (en) 2022-08-25
TW202023608A (zh) 2020-07-01
CR20200492A (es) 2020-11-24
TW201708246A (zh) 2017-03-01
AU2016313684B2 (en) 2020-04-02
KR20180038550A (ko) 2018-04-16
US20200061170A1 (en) 2020-02-27
PE20181517A1 (es) 2018-09-21
JP7506026B2 (ja) 2024-06-25
CN107921111B (zh) 2022-07-26
TW202023607A (zh) 2020-07-01
SG10202001830PA (en) 2020-04-29
TW202024112A (zh) 2020-07-01
US10525114B2 (en) 2020-01-07
TWI722660B (zh) 2021-03-21
CR20180423A (es) 2018-11-19
TW202024110A (zh) 2020-07-01
KR20210122894A (ko) 2021-10-12
AU2016313684A1 (en) 2018-04-12
TWI722655B (zh) 2021-03-21
EA201891874A2 (ru) 2019-01-31
US11065316B2 (en) 2021-07-20
WO2017036936A1 (fr) 2017-03-09
TWI722654B (zh) 2021-03-21
CR20200493A (es) 2020-11-24
MA45073A (fr) 2019-04-03
PE20181164A1 (es) 2018-07-19
TWI722663B (zh) 2021-03-21
CA2996963A1 (fr) 2017-03-09
JP6970974B2 (ja) 2021-11-24
SG10201807588TA (en) 2018-10-30
TWI722657B (zh) 2021-03-21
KR20180093123A (ko) 2018-08-20
AU2018250464B2 (en) 2020-04-09
CA3072922A1 (fr) 2017-03-09
MA43457A1 (fr) 2019-08-30
SG10202001831SA (en) 2020-04-29
MX2018002480A (es) 2018-08-24
TW202024109A (zh) 2020-07-01
EP3341014A1 (fr) 2018-07-04
TW202024115A (zh) 2020-07-01
TWI722662B (zh) 2021-03-21
US20200054729A1 (en) 2020-02-20
US20200323968A1 (en) 2020-10-15
MA43459A1 (fr) 2019-08-30
TWI722664B (zh) 2021-03-21
TW202041233A (zh) 2020-11-16
KR102308798B1 (ko) 2021-10-05
EA201891874A3 (ru) 2019-05-31
MA43461B1 (fr) 2021-03-31

Similar Documents

Publication Publication Date Title
MA43460A1 (fr) Nouveaux peptides, combinaisons de peptides et supports pour utilisation dans le traitementimmunothérapeutique de divers cancers
MA43490A1 (fr) Nouveaux peptides et combinaison de peptides destinés à être utilisés dans l'immunothérapie contre divers cancers
MA44101A (fr) Peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer du sein et d'autres cancers
MA46022B1 (fr) Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de la prostate et d'autres cancers
MA43719B1 (fr) Peptide à utiliser en immunothérapie contre le cancer du poumon non à petites cellules et le cancer du poumon à petites cellules
MA43435B1 (fr) Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre diverses tumeurs (seq id 25 - mrax5-003)
MA46648B2 (fr) Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie du cancer du pancréas et d'autres cancers
MA42045A (fr) Nouveaux peptides et combinaisons de peptides et échafaudages formés de ceux-ci destinés à être utilisés en immunothérapie contre le carcinome colorectal (crc) et d'autres cancers
MA46508A1 (fr) Nouveaux épitopes de cellules et nouvelle combinaison d'épitopes de cellules destinés à être utilisés dans l'immunothérapie du myélome et d'autres cancers
MA43090A1 (fr) Peptides, combinaisons de peptides et médicaments basés sur les cellules pour l'immunothérapie contre le cancer de la vessie urinaire et d'autres cancers
MA42381A (fr) Nouveaux peptides et nouvelle combinaison de peptides à utiliser dans l'immunothérapie du cancer de l' oesophage et d'autres cancers
MA41520B2 (fr) Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
MA42294B1 (fr) Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
MA44551A1 (fr) Nouveaux peptides et nouvelle combinaison de peptides à utiliser en immunothérapie, et procédés pour générer des échafaudages à utiliser contre le cancer du pancréas et d'autres cancers
MA43330B1 (fr) Lymphocytes t transfectés et récepteurs de lymphocytes t destinés à être utilisés en immunothérapie contre des cancers
MA41237B1 (fr) Nouveaux peptides et combinaisons de peptides pour une utilisation en immunothérapie contre le carcinome hépatocellulaire (chc) et autres cancers
MA43328A1 (fr) Lymphocytes t transfectés et récepteurs de lymphocytes t destinés à être utilisés en immunothérapie contre des cancers
MA47367B1 (fr) Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
MA46913B1 (fr) Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
MA46503A1 (fr) Nouveaux épitopes de cellules et nouvelle combinaison d'épitopes de cellules destinés à être utilisés dans l'immunothérapie du myélome et d'autres cancers
MA43596A1 (fr) Nouveaux peptides et nouvelle combinaison de peptides à utiliser dans l'immunothérapie du cancer de l'œsophage et d'autres cancers
MA41664A1 (fr) Nouveaux peptides et nouvelle combinaison de peptides à utiliser en immunothérapie, et procédés pour générer des échafaudages à utiliser contre le cancer du pancréas et d'autres cancers